Logo image of GKOS

GLAUKOS CORP (GKOS) Stock Fundamental Analysis

NYSE:GKOS - New York Stock Exchange, Inc. - US3773221029 - Common Stock - Currency: USD

100.14  +2.54 (+2.6%)

After market: 100.14 0 (0%)

Fundamental Rating

4

GKOS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of GKOS is average, but there are quite some concerns on its profitability. GKOS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year GKOS has reported negative net income.
In the past year GKOS has reported a negative cash flow from operations.
GKOS had negative earnings in each of the past 5 years.
In the past 5 years GKOS reported 4 times negative operating cash flow.
GKOS Yearly Net Income VS EBIT VS OCF VS FCFGKOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

GKOS has a Return On Assets of -12.80%. This is comparable to the rest of the industry: GKOS outperforms 57.22% of its industry peers.
GKOS has a Return On Equity of -16.19%. This is in the better half of the industry: GKOS outperforms 63.64% of its industry peers.
Industry RankSector Rank
ROA -12.8%
ROE -16.19%
ROIC N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
GKOS Yearly ROA, ROE, ROICGKOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30

1.3 Margins

GKOS has a Gross Margin of 75.75%. This is amongst the best in the industry. GKOS outperforms 89.30% of its industry peers.
In the last couple of years the Gross Margin of GKOS has declined.
The Profit Margin and Operating Margin are not available for GKOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
GKOS Yearly Profit, Operating, Gross MarginsGKOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

GKOS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GKOS has been increased compared to 1 year ago.
GKOS has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, GKOS has an improved debt to assets ratio.
GKOS Yearly Shares OutstandingGKOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GKOS Yearly Total Debt VS Total AssetsGKOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

GKOS has an Altman-Z score of 15.98. This indicates that GKOS is financially healthy and has little risk of bankruptcy at the moment.
GKOS has a Altman-Z score of 15.98. This is amongst the best in the industry. GKOS outperforms 94.12% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that GKOS is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, GKOS is in line with its industry, outperforming 59.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z 15.98
ROIC/WACCN/A
WACC8.79%
GKOS Yearly LT Debt VS Equity VS FCFGKOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

GKOS has a Current Ratio of 6.49. This indicates that GKOS is financially healthy and has no problem in meeting its short term obligations.
GKOS's Current ratio of 6.49 is amongst the best of the industry. GKOS outperforms 85.03% of its industry peers.
A Quick Ratio of 5.62 indicates that GKOS has no problem at all paying its short term obligations.
GKOS's Quick ratio of 5.62 is amongst the best of the industry. GKOS outperforms 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 6.49
Quick Ratio 5.62
GKOS Yearly Current Assets VS Current LiabilitesGKOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

GKOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.34%, which is quite impressive.
GKOS shows a strong growth in Revenue. In the last year, the Revenue has grown by 23.92%.
Measured over the past years, GKOS shows a quite strong growth in Revenue. The Revenue has been growing by 10.10% on average per year.
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.57%
Revenue 1Y (TTM)23.92%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%24.58%

3.2 Future

The Earnings Per Share is expected to grow by 32.42% on average over the next years. This is a very strong growth
GKOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.64% yearly.
EPS Next Y54.21%
EPS Next 2Y40.7%
EPS Next 3Y36.88%
EPS Next 5Y32.42%
Revenue Next Year26.94%
Revenue Next 2Y27.27%
Revenue Next 3Y26.47%
Revenue Next 5Y32.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
GKOS Yearly Revenue VS EstimatesGKOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 500M 1B 1.5B
GKOS Yearly EPS VS EstimatesGKOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GKOS. In the last year negative earnings were reported.
Also next year GKOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GKOS Price Earnings VS Forward Price EarningsGKOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -500 -1K -1.5K -2K -2.5K

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GKOS Per share dataGKOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

GKOS's earnings are expected to grow with 36.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.7%
EPS Next 3Y36.88%

More info and screens

0

5. Dividend

5.1 Amount

GKOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GLAUKOS CORP

NYSE:GKOS (6/16/2025, 8:04:00 PM)

After market: 100.14 0 (0%)

100.14

+2.54 (+2.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-30 2025-04-30/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners101.3%
Inst Owner Change0.35%
Ins Owners3.28%
Ins Owner Change2.01%
Market Cap5.72B
Analysts82.86
Price Target126.14 (25.96%)
Short Float %6.07%
Short Ratio3.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.84%
Min EPS beat(2)-2.27%
Max EPS beat(2)37.95%
EPS beat(4)3
Avg EPS beat(4)19.81%
Min EPS beat(4)-2.27%
Max EPS beat(4)42.53%
EPS beat(8)5
Avg EPS beat(8)7.6%
EPS beat(12)7
Avg EPS beat(12)-0.45%
EPS beat(16)11
Avg EPS beat(16)6.78%
Revenue beat(2)2
Avg Revenue beat(2)2.35%
Min Revenue beat(2)2.01%
Max Revenue beat(2)2.69%
Revenue beat(4)4
Avg Revenue beat(4)3.45%
Min Revenue beat(4)2.01%
Max Revenue beat(4)5.53%
Revenue beat(8)8
Avg Revenue beat(8)3.57%
Revenue beat(12)12
Avg Revenue beat(12)3.82%
Revenue beat(16)16
Avg Revenue beat(16)4.35%
PT rev (1m)-4.13%
PT rev (3m)-26.62%
EPS NQ rev (1m)2.7%
EPS NQ rev (3m)2.1%
EPS NY rev (1m)0%
EPS NY rev (3m)18.68%
Revenue NQ rev (1m)0.05%
Revenue NQ rev (3m)-0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.15
P/FCF N/A
P/OCF N/A
P/B 7.49
P/tB 13.01
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.93
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS7.08
BVpS13.37
TBVpS7.7
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.8%
ROE -16.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 75.75%
FCFM N/A
ROA(3y)-13.08%
ROA(5y)-11.18%
ROE(3y)-22.32%
ROE(5y)-18.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.81%
GM growth 5Y-2.05%
F-Score5
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.17%
Cap/Sales 1.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.49
Quick Ratio 5.62
Altman-Z 15.98
F-Score5
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)57.91%
Cap/Depr(5y)71.69%
Cap/Sales(3y)6.26%
Cap/Sales(5y)7.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.57%
EPS Next Y54.21%
EPS Next 2Y40.7%
EPS Next 3Y36.88%
EPS Next 5Y32.42%
Revenue 1Y (TTM)23.92%
Revenue growth 3Y9.26%
Revenue growth 5Y10.1%
Sales Q2Q%24.58%
Revenue Next Year26.94%
Revenue Next 2Y27.27%
Revenue Next 3Y26.47%
Revenue Next 5Y32.64%
EBIT growth 1Y16.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.69%
EBIT Next 3Y43.91%
EBIT Next 5Y43.81%
FCF growth 1Y48.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.55%
OCF growth 3YN/A
OCF growth 5YN/A